Robert Francomano
Keine laufenden Positionen mehr
Vermögen: 36 355 $ am 30.04.2024
Profil
Robert M.
Francomano served as the Chief Commercial Officer at Stemline Therapeutics, Inc. from 2016 to 2021.
He then held the position of Chief Commercial Officer & Senior Vice President at SELLAS Life Sciences Group, Inc. from 2022 to 2024.
Prior to his roles in the pharmaceutical industry, he obtained an undergraduate degree from Siena College and an MBA from the University of Albany.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.01.2024 | 23 918 ( 0,04% ) | 36 355 $ | 30.04.2024 |
Ehemalige bekannte Positionen von Robert Francomano
| Unternehmen | Position | Ende |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 31.03.2024 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2021 |
Ausbildung von Robert Francomano
| Siena College | Undergraduate Degree |
| University of Albany | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
